Introduction to Risk Stratification in Kidney Cancer

Identifying accurate predictors of recurrence in renal cell carcinoma (RCC) remains essential for personalized patient care. The GRANT score RCC prognosis model provides a streamlined method to stratify risk using four routinely available clinical factors: grade, age, nodal status, and tumor size. Consequently, this prospective external validation within the ECOG-ACRIN EA8143 PROSPER trial confirms its reliability for surgically treated patients.

The study analyzed 714 patients to determine the accuracy of the GRANT score in a modern trial setting. Specifically, researchers categorized patients into favorable (0\u20131 risk factors) and unfavorable (2\u20134 risk factors) groups. Results revealed that the favorable group achieved a significantly longer median relapse-free survival (RFS) of 61.1 months. In contrast, the unfavorable group reached only 36.9 months. Moreover, the hazard ratio for RFS was 0.36, highlighting a substantial difference in recurrence risk between groups.

Clinical Utility of the GRANT Score RCC Prognosis

The model demonstrated consistent discrimination with a C-index of 0.61 for RFS and 0.63 for overall survival (OS). Furthermore, because it relies on standard pathology and clinical data, this tool offers a practical alternative to more complex scoring systems. Therefore, clinicians can use these results to refine follow-up schedules and potentially select candidates for adjuvant therapies. Additionally, the GRANT score maintains its performance across different patient cohorts. However, practitioners should still integrate these findings with local guidelines. Consequently, the GRANT score remains a robust tool for routine urological oncology practice.

Frequently Asked Questions

What parameters are used in the GRANT score?

The GRANT score integrates four key factors: Fuhrman/ISUP grade, patient age, pathological nodal status, and pathological tumor size.

How does the GRANT score help in kidney cancer management?

It classifies patients into favorable or unfavorable risk groups. This allows for tailored surveillance and informed discussions regarding the risk of relapse after surgery.

Is the GRANT score valid for all types of RCC?

While primarily validated for clear-cell and papillary subtypes, this specific prospective analysis within the PROSPER trial further confirms its utility in a modern clinical cohort.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.

References

Buti S et al. A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trial. Oncologist. 2026 Feb 15. doi: undefined. PMID: 41693026.

Buti S et al. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol. 2017;28(11):2747-2753.

Buti S et al. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database. Sci Rep. 2019;9:13218.